BofA/Merrill Lynch Upgrades Acadia Pharmaceuticals (ACAD) to Buy
Tweet
Share
E-mail
Get Alerts ACAD Hot Sheet
Price: $22.09 +2.17%
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Rating Summary:
17 Buy, 10 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 18 | Down: 12 | New: 24
Join SI Premium – FREE
BofA/Merrill Lynch upgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Neutral to Buy with a price target of $35.00.
For an analyst ratings summary and ratings history on Acadia Pharmaceuticals click here. For more ratings news on Acadia Pharmaceuticals click here.
Shares of Acadia Pharmaceuticals closed at $22.99 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualcomm (QCOM) PT Raised to $195 at BofA Securities
- Taysha Gene Therapies (TSHA) PT Raised to $10 at BofA Securities
- Buy gold stocks as valuations are cheap amid macro tension: BofA
Create E-mail Alert Related Categories
UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
